Literature DB >> 16556449

Abeta42 gene vaccination reduces brain amyloid plaque burden in transgenic mice.

Baoxi Qu1, Philip J Boyer, Stephen Albert Johnston, Linda S Hynan, Roger N Rosenberg.   

Abstract

OBJECTIVE: To demonstrate that in APPswe/PS1DeltaE9 transgenic mice, gene gun mediated Abeta42 gene vaccination elicits a high titer of anti-Abeta42 antibodies causal of a significant reduction of Abeta42 deposition in brain.
METHODS: Gene gun immunization is conducted with transgenic mice using the Abeta42 gene in a bacterial plasmid with the pSP72-E3L-Abeta42 construct. Enzyme-linked immunoabsorbent assays (ELISA) and Western blots are used to monitor anti-Abeta42 antibody levels in serum and Abeta42 levels in brain tissues. Enzyme-linked immunospot (ELISPOT) assays are used for detection of peripheral blood T cells to release gamma-interferon. Immunofluorescence detection of Abeta42 plaques and quantification of amyloid burden of brain tissue were measured and sections were analyzed with Image J (NIH) software.
RESULTS: Gene gun vaccination with the Abeta42 gene resulted in high titers of anti-Abeta42 antibody production of the Th2-type. Levels of Abeta42 in treated transgenic mouse brain were reduced by 60-77.5%. The Mann-Whitney U-test P=0.0286.
INTERPRETATION: We have developed a gene gun mediated Abeta42 gene vaccination method that is efficient to break host Abeta42 tolerance without using adjuvant and induces a Th2 immune response. Abeta42 gene vaccination significantly reduces the Abeta42 burden of the brain in treated APPswe/PS1DeltaE9 transgenic mice with no overlap between treated and control mice.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16556449      PMCID: PMC1531642          DOI: 10.1016/j.jns.2006.02.006

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  40 in total

1.  Gene gun bombardment with gold particles displays a particular Th2-promoting signal that over-rules the Th1-inducing effect of immunostimulatory CpG motifs in DNA vaccines.

Authors:  Richard Weiss; Sandra Scheiblhofer; Johann Freund; Fatima Ferreira; Ian Livey; Josef Thalhamer
Journal:  Vaccine       Date:  2002-08-19       Impact factor: 3.641

Review 2.  Amyloid-beta immunotherapy for Alzheimer's disease: the end of the beginning.

Authors:  Dale Schenk
Journal:  Nat Rev Neurosci       Date:  2002-10       Impact factor: 34.870

3.  High-level generation of polyclonal antibodies by genetic immunization.

Authors:  Ross S Chambers; Stephen Albert Johnston
Journal:  Nat Biotechnol       Date:  2003-08-10       Impact factor: 54.908

Review 4.  Immunotherapeutic approaches to Alzheimer's disease.

Authors:  Alon Monsonego; Howard L Weiner
Journal:  Science       Date:  2003-10-31       Impact factor: 47.728

5.  Genetic immunization is a simple method for eliciting an immune response.

Authors:  D C Tang; M DeVit; S A Johnston
Journal:  Nature       Date:  1992-03-12       Impact factor: 49.962

6.  Generation and characterization of the humoral immune response to DNA immunization with a chimeric beta-amyloid-interleukin-4 minigene.

Authors:  Anahit Ghochikyan; Vitaly Vasilevko; Irina Petrushina; Nina Movsesyan; Davit Babikyan; Wenqiang Tian; Nadya Sadzikava; Ted M Ross; Elizabeth Head; David H Cribbs; Michael G Agadjanyan
Journal:  Eur J Immunol       Date:  2003-12       Impact factor: 5.532

7.  Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease.

Authors:  Christoph Hock; Uwe Konietzko; Johannes R Streffer; Jay Tracy; Andri Signorell; Britta Müller-Tillmanns; Ulrike Lemke; Katharina Henke; Eva Moritz; Esmeralda Garcia; M Axel Wollmer; Daniel Umbricht; Dominique J F de Quervain; Marc Hofmann; Alessia Maddalena; Andreas Papassotiropoulos; Roger M Nitsch
Journal:  Neuron       Date:  2003-05-22       Impact factor: 17.173

8.  HIV-1 p55Gag encoded in the lysosome-associated membrane protein-1 as a DNA plasmid vaccine chimera is highly expressed, traffics to the major histocompatibility class II compartment, and elicits enhanced immune responses.

Authors:  Ernesto T A Marques; Priya Chikhlikar; Luciana Barros de Arruda; Ihid C Leao; Yang Lu; Justin Wong; Juei-Suei Chen; Barry Byrne; J Thomas August
Journal:  J Biol Chem       Date:  2003-06-24       Impact factor: 5.157

9.  The CTA1-DD vaccine adjuvant binds to human B cells and potentiates their T cell stimulating ability.

Authors:  A Eriksson; N Lycke
Journal:  Vaccine       Date:  2003-12-12       Impact factor: 3.641

10.  Reversible memory loss in a mouse transgenic model of Alzheimer's disease.

Authors:  Linda A Kotilinek; Brian Bacskai; Marcus Westerman; Takeshi Kawarabayashi; Linda Younkin; Bradley T Hyman; Steven Younkin; Karen H Ashe
Journal:  J Neurosci       Date:  2002-08-01       Impact factor: 6.167

View more
  21 in total

Review 1.  The Role of Inflammatory Mediators in the Pathogenesis of Alzheimer's Disease.

Authors:  Gholamreza Azizi; Shadi S Navabi; Ahmed Al-Shukaili; Mir H Seyedzadeh; Reza Yazdani; Abbas Mirshafiey
Journal:  Sultan Qaboos Univ Med J       Date:  2015-08-24

2.  A noninflammatory immune response in aged DNA Aβ42-immunized mice supports its safety for possible use as immunotherapy in AD patients.

Authors:  Doris Lambracht-Washington; Roger N Rosenberg
Journal:  Neurobiol Aging       Date:  2014-12-12       Impact factor: 4.673

Review 3.  Biodegradable nanoparticles for cytosolic delivery of therapeutics.

Authors:  Jaspreet K Vasir; Vinod Labhasetwar
Journal:  Adv Drug Deliv Rev       Date:  2007-06-26       Impact factor: 15.470

4.  Intradermal active full-length DNA Aβ42 immunization via electroporation leads to high anti-Aβ antibody levels in wild-type mice.

Authors:  Roger N Rosenberg; Min Fu; Doris Lambracht-Washington
Journal:  J Neuroimmunol       Date:  2018-06-11       Impact factor: 3.478

5.  DNA beta-amyloid(1-42) trimer immunization for Alzheimer disease in a wild-type mouse model.

Authors:  Doris Lambracht-Washington; Bao-Xi Qu; Min Fu; Todd N Eagar; Olaf Stüve; Roger N Rosenberg
Journal:  JAMA       Date:  2009-10-28       Impact factor: 56.272

6.  DNA immunization against amyloid beta 42 has high potential as safe therapy for Alzheimer's disease as it diminishes antigen-specific Th1 and Th17 cell proliferation.

Authors:  Doris Lambracht-Washington; Bao-Xi Qu; Min Fu; Larry D Anderson; Olaf Stüve; Todd N Eagar; Roger N Rosenberg
Journal:  Cell Mol Neurobiol       Date:  2011-04-06       Impact factor: 5.046

Review 7.  Amyloid-beta immunotherapy for Alzheimer's disease.

Authors:  H J Fu; B Liu; J L Frost; C A Lemere
Journal:  CNS Neurol Disord Drug Targets       Date:  2010-04       Impact factor: 4.388

8.  A peptide prime-DNA boost immunization protocol provides significant benefits as a new generation Aβ42 DNA vaccine for Alzheimer disease.

Authors:  Doris Lambracht-Washington; Bao-xi Qu; Min Fu; Larry D Anderson; Todd N Eagar; Olaf Stüve; Roger N Rosenberg
Journal:  J Neuroimmunol       Date:  2012-10-01       Impact factor: 3.478

9.  Abeta42 gene vaccine prevents Abeta42 deposition in brain of double transgenic mice.

Authors:  Bao-Xi Qu; Qun Xiang; Liping Li; Stephen Albert Johnston; Linda S Hynan; Roger N Rosenberg
Journal:  J Neurol Sci       Date:  2007-06-15       Impact factor: 3.181

Review 10.  DNA Aβ42 vaccination as possible alternative immunotherapy for Alzheimer disease.

Authors:  Roger N Rosenberg; Doris Lambracht-Washington
Journal:  JAMA Neurol       Date:  2013-06       Impact factor: 18.302

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.